Breaking News, Collaborations & Alliances, Trials & Filings

MAP Gains Allergan Milestone

Migraine med NDA filing triggers collaboration payment

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

MAP Pharmaceuticals‘ NDA for Levadex, an orally inhaled migraine drug for the potential acute treatment of migraine in adults, has been accepted for filing by the FDA. The application has a goal date of March 26, 2012 under PDUFA. FDA’s acceptance of the filing has triggered a $20 million milestone payment from development partner Allergan to MAP. “We are very pleased with the FDA’s acceptance of the filing of our Levadex NDA submission as it is a significant achievement...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters